Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-04-26 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2017年第一季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (440 characters) indicating that the company has approved and will disclose its 2017 first quarter report on a specified website. It does not contain the actual financial data or detailed report content but rather informs investors about the availability of the quarterly report. According to the 'MENU VS MEAL' rule, such a brief notice about report disclosure is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2017-04-26 Chinese
关于延长Xcovery公司可转换公司债兑付期限暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 贝达药业股份有限公司 regarding the extension of the maturity date of convertible bonds issued by Xcovery Holding Company LLC, a company in which 贝达药业 has invested. The text details the background of the transaction, the board and shareholder approvals, the amounts involved, and the strategic rationale. It is a formal disclosure about a financing-related transaction and its approval process, including related party considerations. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is a regulatory announcement about a capital/financing update, specifically about extending the maturity of convertible bonds and related shareholder approvals. The document length is 3776 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-04-26 Chinese
2017年第一季度报告全文
Regulatory Filings
2017-04-26 Chinese
2016年度股东大会的法律意见书
AGM Information Classification · 100% confidence The document is a legal opinion letter from a law firm regarding the 2016 Annual General Meeting (AGM) of Betta Pharmaceuticals Co., Ltd. It details the procedures of the AGM, the qualifications of attendees, the agenda items discussed, and the voting results. The document focuses on the legality and validity of the AGM process and voting outcomes, rather than presenting the actual annual report or financial statements. It is not the annual report itself but a legal opinion related to the AGM. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions on the meeting.
2017-04-26 Chinese
关于认购美国Xcovery公司新发行D轮优先股暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 贝达药业股份有限公司 regarding the subscription to newly issued Series D preferred shares of the US company Xcovery. It details the transaction terms, the approval process including board and shareholder meetings, and the related party nature of the transaction. The document includes information about the strategic investment, the voting and approval procedures, and financial figures related to the transaction. It is not a full financial report, earnings release, or regulatory certification. It is a detailed announcement about a capital financing activity involving issuance and subscription of shares. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2017-04-26 Chinese
2016年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2016 Annual General Meeting (AGM) resolution announcement for Betta Pharmaceuticals Co., Ltd. It details the meeting attendance, voting procedures, and the voting results on various agenda items including the 2016 board work report, supervisory board report, financial statements, annual report, profit distribution plan, remuneration, auditor appointment, and other corporate matters. The document is a formal announcement of the resolutions passed at the AGM, including voting results and legal opinions on the meeting's validity. It does not contain the full annual report or financial statements themselves but reports on the meeting outcomes and shareholder votes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, supporting this classification with high confidence.
2017-04-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.